In a cohort of 66 patients with CCA and 62 with PSC, a panel combining serum levels of PKM2, CYFR21.1, MUC5AC and GGT was able to differentiate CCA from PSC with test sensitivity of 82% and specificity of 90% (AUC 0.90) (134). This evidence concerns the gene PKM and cholangiocarcinoma.